Sirona Biochem Corp. announced that the clinical trial results, for novel anti-aging compound TFC-1326, have exceeded even high expectations on key criteria. The trial, which was completed by a leading contract research organization in Paris, France, was independently financed by Sirona to ensure that results can be shared with interested partners, without restrictions.

Full results will be published in a scientific journal. The clinical trial was designed to assess the compound's efficacy to reverse aging facial skin, including restoring lost volume and reducing fine wrinkles. The formulation is a cream base with TFC-1326 at a concentration of 1% and no other active ingredient.

The following key scientific results were shown during the trial: 37% increase in skin density. 54% decrease in H202 (exceptional antioxidant). Oxidation is a major cause of skin aging.

54% decrease in IL-8 (exceptional anti-inflammatory). Inflammation is also a major cause of skin aging. 25% increase in skin radiance.

14% improvement in facial skin laxity, which is a remodeling effect on the oval of the face. The following results were collected from participants: 80% of participants felt their skin was firmer. 90% of participants felt an improvement in the quality of the skin.

100% of participants reported the product was well tolerated, even on sensitive skin. 95% of participants reported being happy with the product. 75% of participants reported a visible reduction in wrinkles.

90% reported improved skin hydration. The results support the strong preclinical data including clinical safety data. A basic formulation was utilized in the clinical trial to confirm all benefits were specifically attributable to TFC-1326 and not other active ingredients.

Sirona is currently engaging industry experts to determine the best path forward to commercialize TFC-1326. Further updates will be provided once the strategy is finalized. The concept for the anti-aging library related to TFC-1326 was initiated by Chief Scientific officer Dr. Géraldine Deliencourt-Godefroy.

The innovative chemistry is based on the naturally occurring antifreeze glycoproteins found in polar fish. TFC-1326 is now a clinically proven breakthrough anti-aging compound. Sirona has achieved the goal to develop a non-invasive anti-aging skin care compound which is safe, easy to use and truly effective.

TFC-1326 could be a stand-alone product for anti-aging or an adjunctive option to Botox® and dermal filler treatments depending on consumer goals.